Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug – MOSAEC

Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.

Author: Gina Kolata

Written by

in

Clinical Trials, donanemab, Drugs (Pharmaceuticals), Eisai Co Ltd, Eli Lilly and Company, Food and Drug Administration, Leqembi (Drug), Memory, United States

More posts